natgillin/translations-raw huggingface dataset:
A metabolism study in diabetic patients who received insulin glargine alone indicates that insulin glargine is rapidly metabolised at the carboxyl terminus of the B chain to form two active metabolites, M1 (21A-Gly-insulin) and M2 (21A-Gly-des-30B-Thr-insulin).
Študija presnove pri sladkornih bolnikih, ki so prejemali samo insulin glargin, je pokazala, da se insulin glargin hitro presnovi na karboksilnem koncu verige B. Tako nastaneta dva aktivna presnovka, M1 (21A-Gly-insulin) in M2 (21A-Gly-des-30B-Thr-insulin).
If your blood sugar gets too low, see the advice in the box at the end of this leaflet.
Če se vam krvni sladkor preveč zniža, glejte nasvet v okviru na koncu tega navodila.
Following administration of a single dose of an oral contraceptive medicinal product (ethinylestradiol 0.03 mg/levonorgestrel 0.15 mg) 1 hour before or 11 hours after 10 mcg lixisenatide, the Cmax, AUC, t1/2 and tmax of ethinylestradiol and levonorgestrel were unchanged.
Po uporabi enkratnega odmerka peroralnega kontraceptiva (0,03 mg etinilestradiola in 0,15 mg levonorgestrela) 1 uro pred ali 11 ur po 10 mcg liksisenatida se Cmax, AUC, t1/2 in tmax etinilestradiola in levonorgestrela niso spremenili.
Suliqua must not be mixed with any other insulin or diluted.
Zdravila Suliqua se ne sme mešati z nobenim drugim insulinom in se ga ne sme redčiti.
Some medicines can change your blood sugar level.
Nekatera zdravila lahko spremenijo koncentracijo sladkorja v krvi.
At the end of the run-in period, patients who remained inadequately controlled (HbA1c between 7% and 10%) were randomised to either Suliqua, insulin glargine or lixisenatide.
Na koncu obdobja uvajanja so bolnike, ki so ostali neustrezno urejeni (HbA1c med 7 % in 10 %), randomizirali ali na zdravilo Suliqua ali na insulin glargin ali na liksisenatid.
Based on these results, no dose adjustment for warfarin is required when co-administered with lixisenatide; however, frequent monitoring of INR in patients on warfarin and/or coumarin derivatives is recommended at the time of initiation or ending of lixisenatide treatment.
Na podlagi teh rezultatov odmerka varfarina med sočasno uporabo z liksisenatidom ni treba prilagoditi, je pa v času uvedbe ali končanja zdravljenja z liksisenatidom priporočljivo pogosto kontrolirati INR bolnikov, ki prejemajo varfarin in/ali kumarinske derivate.
Needles must not be re-used.
Igel se ne sme ponovno uporabiti.
• For twice daily basal insulin or insulin glargine (300 units/ml), the total daily dose previously used should be reduced by 20% to choose the Suliqua starting dose.
• V primeru predhodne uporabe bazalnega insulina ali insulina glargin (300 enot/ml) dvakrat na dan je treba za izbiro začetnega odmerka zdravila Suliqua celotni predhodno uporabljani dnevni odmerek zmanjšati za 20 %.
Suliqua is not recommended in women of childbearing potential not using contraception.
Zdravila Suliqua ni priporočljivo uporabljati pri ženskah v rodni dobi, ki ne uporabljajo kontracepcije.
This can help to spot mild hypoglycaemic episodes.
To lahko pomaga odkriti blage hipoglikemije.
• Patients who are blind or with poor vision must be instructed to always get assistance from another person who has good vision and is trained in using insulin glargine/lixisenatide pen device.
• Slepim ali slabovidnim bolnikom je treba naročiti, da morajo vedno dobiti pomoč druge osebe, ki dobro vidi in je usposobljena za uporabo napolnjenega injekcijskega peresnika z insulinom glarginom/liksisenatidom.
The following table describes the rate of documented symptomatic hypoglycaemia (≤3.9 mmol/L) and severe hypoglycaemia for both Suliqua and the comparator.
Naslednja preglednica prikazuje delež dokumentiranih simptomatskih hipoglikemij (≤ 3,9 mmol/l) in hudih hipoglikemij z zdravilom Suliqua in primerjalnim zdravilom.
In rare cases, the presence of such antibodies may necessitate adjustment of the Suliqua dose in order to correct a tendency for hyperglycaemia or hypoglycaemia.
V redkih primerih je zaradi prisotnosti takšnih protiteles treba prilagoditi odmerek zdravila Suliqua, da bi odpravili nagnjenost k hiperglikemiji ali hipoglikemiji.
Since Suliqua may cause stomach side effects, the medicine has not been studied in patients with severe stomach or gut problems.
Ker lahko zdravilo Suliqua povzroča neželene učinke na prebavilih, ni raziskano pri bolnikih s hudimi težavami z želodcem ali črevesjem.
Results at 30 weeks - Add-on to metformin clinical study (mITT population) Suliqua
Rezultati po 30 tednih - Klinična študija dodatka metforminu (populacija mZNZ) Zdravilo Suliqua
This type 2 diabetes population had the following characteristics: Mean age was 60.0 years with the majority (56.3%) being aged of 50 to 64 years, and 53.3 percent were female.
Ta populacija s sladkorno boleznijo tipa 2 je imela naslednje značilnosti: povprečna starost je bila 60,0 let; večina bolnikov (56,3 %) je bila starih od 50 do 64 let.
These factors include: - change in the injection area - improved insulin sensitivity (e.g. by removal of stress factors) - unaccustomed, increased or prolonged physical activity - intercurrent illness (e.g. vomiting, diarrhoea) - inadequate food intake - missed meals - alcohol consumption - certain uncompensated endocrine disorders, (e.g. in hypothyroidism and in anterior pituitary or adrenocortical insufficiency) - concomitant treatment with certain other medicinal products (see section 4.5).
Med takšnimi dejavniki so: - sprememba predela injiciranja, - izboljšana občutljivost za insulin (npr. zaradi odstranitve stresnih dejavnikov), - nevajena, intenzivnejša ali dolgotrajnejša telesna dejavnost, - sočasna bolezen (npr. bruhanje, driska), - nezadostno uživanje hrane, - izpuščeni obroki, - pitje alkohola, - določene nekompenzirane endokrine motnje (npr. hipotiroidizem, insuficienca sprednjega režnja hipofize ali insuficienca skorje nadledvične žleze), - sočasno zdravljenje z določenimi drugimi zdravili (glejte poglavje 4.5).
As lixisenatide is cleared primarily by the kidney, no pharmacokinetic study has been performed in patients with acute or chronic hepatic impairment.
Liksisenatid se odstrani predvsem skozi ledvice, zato farmakokinetičnih študij pri bolnikih z akutno ali kronično okvaro jeter niso izvedli.
Turn the dose selector until the dose pointer lines up with your dose.
Zavrtite izbirnik odmerka, dokler kazalnik odmerka ni nastavljen na vaš odmerek.
No animal studies have been conducted with the combination of insulin glargine and lixisenatide to evaluate repeated dose toxicity, carcinogenesis, genotoxicity, or toxicity to reproduction.
Na živalih niso izvedli študij s kombinacijo insulina glargin in liksisenatida za oceno toksičnosti ponavljajočih odmerkov, kancerogenosti, genotoksičnosti ali vpliva na sposobnost razmnoževanja.
A. Take a new needle and peel off the protective seal.
A. Vzemite novo iglo in odstranite zaščitno prelepko.
In addition, under the influence of sympatholytic medicinal products such as beta-blockers, clonidine, guanethidine and reserpine, the signs of adrenergic counter-regulation may be reduced or absent.
Poleg tega se lahko pod vplivom simpatikolitičnih zdravil, npr. antagonistov adrenergičnih receptorjev beta, klonidina, gvanetidina in rezerpina, znaki adrenergične protiregulacije zmanjšajo ali izginejo.
It is given, with metformin, when other medicines are not enough on their own to control your blood sugar levels.
Uporablja se, skupaj z metforminom, če druga zdravila sama ne zadoščajo za obvladovanje koncentracije krvnega sladkorja.
The most frequently reported adverse reactions during treatment with Suliqua were hypoglycaemia and gastrointestinal adverse reactions (see section 'Description of selected adverse reactions' below).
Najpogostejši neželeni učinki med zdravljenjem z zdravilom Suliqua so bili hipoglikemija in neželeni učinki na prebavilih (glejte poglavje "Opis izbranih neželenih učinkov", spodaj).
The MAH shall ensure that, in each Member State where Suliqua is marketed, all healthcare professionals who are expected to prescribe, dispense and patients who are expected to use Suliqua, have access to/are provided with the following educational package:
Imetnik dovoljenja za promet z zdravilom bo v vseh državah članicah, kjer bo zdravilo Suliqua na trgu, poskrbel, da bodo vsi zdravstveni delavci, ki bodo predvidoma predpisovali ali izdajali to zdravilo, in vsi bolniki, ki ga bodo predvidoma uporabljali, imeli dostop do naslednjega izobraževalnega kompleta oziroma bodo dobili ta komplet:
There is no experience with Suliqua in children and adolescents aged less than 18 years, therefore, the use of Suliqua is not recommended in this age group.
Izkušenj z zdravilom Suliqua pri otrocih in mladostnikih, mlajših od 18 let, ni, zato zdravila Suliqua v tej starostni skupini ni priporočljivo uporabljati.
For more information, see the box at the end of this leaflet.
Za več informacij glejte okvir na koncu tega navodila.
• The prescription should mention the pre-filled pen type you need (Suliqua 10-40 pen or 30-60 pen) and the number of dose steps to be injected.
• Na receptu mora biti navedena vrsta napolnjenega injekcijskega peresnika, ki jo potrebujete (peresnik Suliqua 10-40 ali peresnik Suliqua 30-60) in število odmernih korakov, ki jih morate injicirati.
Hypoglycaemia may occur if the dose of Suliqua is higher than required.
Hipoglikemija se lahko pojavi, če je odmerek zdravila Suliqua večji, kot je potrebno.
E. After holding and slowly counting to 10, release the injection button.
E. Potem, ko ste gumb držali in počasi prešteli do 10, gumb za injiciranje spustite.
It is not known if Suliqua passes into your milk.
Ni znano, ali zdravilo Suliqua prehaja v materino mleko.
• you have severe kidney disease or you are on dialysis as the use of this medicine will not be recommended.
• če imate hudo bolezen ledvic ali ste na dializi, ker uporaba tega zdravila v tem primeru ni priporočljiva.
If you have kidney or liver problems If you have kidney or liver problems, talk to your doctor as you may need a lower dose.
Če imate težave z ledvicami ali jetri, se posvetujte z zdravnikom, ker boste morda potrebovali manjši odmerek.
This pen is olive coloured with a brown injection button.
Ta peresnik je olivne barve in ima rjav gumb za injiciranje.
Suliqua with alcohol
Zdravilo Suliqua skupaj z alkoholom
Frequency Very common Common
Zelo pogosti
Suliqua has not been studied in combination with DPP-4 inhibitors, sulfonylureas, glinides, pioglitazone and SGLT-2 inhibitors.
Zdravilo Suliqua ni raziskano v kombinaciji z zaviralci DPP-4, sulfonilsečninami, glinidi, pioglitazonom in zaviralci SGLT-2.
For in use storage conditions, see section 6.3
Za pogoje shranjevanja peresnikov, ki so v uporabi, glejte poglavje 6.3.
Read the Package Leaflet and these Instructions for Use first
Najprej preberite navodilo za uporabo in ta navodila
Use only clear, colourless solution.
Uporabite le bistro, brezbarvno raztopino.
• Changes where the injection is given: If you inject Suliqua too often in the same place, you may develop dents at the site, caused by a loss of fat under the skin (lipoatrophy) or you may develop lumps, caused by a build up of fat under the skin (lipohypertrophy).
• Spremembe na mestu injiciranja: Če si zdravilo Suliqua prepogosto injicirate na isto mesto, se vam lahko tam pojavijo vdolbine, ki so posledica izginotja podkožnega maščevja (lipoatrofija), ali se pojavijo bulice, ki so posledica kopičenja podkožnega maščevja (lipohipertrofija).
A large amount of data on pregnant women (more than 1,000 pregnancy outcomes) with insulin glargine indicate no specific adverse effects of insulin glargine on pregnancy and no specific malformative nor feto/neonatal toxicity of insulin glargine.
Številni podatki o insulinu glargin v nosečnosti (več kot 1.000 izidov nosečnosti) ne kažejo specifičnih neželenih učinkov insulina glargin na nosečnost; prav tako ne kažejo, da bi insulin glargin povzročal specifične malformacije ali fetotoksične učinke/toksične učinke na novorojenčka.
• If you have any questions about your treatment speak to your healthcare professional.
• Če imate vprašanja o svojem zdravljenju, se posvetujte z zdravnikom.
• Do not select a dose or press the injection button without a needle attached.
• Ne izberite odmerka in ne pritisnite gumba za injiciranje, če na peresniku ni nameščena igla.
End of study (mean)
Na koncu študije (povprečje)
Use of glucagon-like peptide-1 (GLP-1) receptor agonists has been associated with a risk of developing acute pancreatitis.
Uporabo agonistov receptorjev glukagonu podobnega peptida 1 (GLP-1, glucagon-like peptide-1) so povezovali s tveganjem za pojav akutnega pankreatitisa.
• Healthcare Professional Guide;
• Vodnik za zdravstvene delavce,
It is recommended to optimise glycaemic control via dose adjustment based on fasting plasma glucose (see section 5.1).
Urejenost glikemije je priporočljivo optimizirati s prilagajanjem odmerka glede na glukozo v plazmi na tešče (glejte poglavje 5.1).
Do not over-tighten.
Ne privijte je preveč.
• Oestrogens and progestogens, such as in the contraceptive pill for birth control or use of oestrogens for bone loss (osteoporosis).
• Estrogene in progestagene, na primer v kontracepcijskih tabletah za uravnavanje rojstev ali estrogene zaradi osteoporoze (izgube kostne mase).
Some medicines such as antibiotics, oral contraceptives, statins (medicines like atorvastatin to lower cholesterol), acidresistant tablets or capsules that should not stay too long in your stomach may need to be taken at least one hour before or four hours after your Suliqua injection.
Nekatera zdravila, na primer antibiotike, peroralne kontraceptive, statine (zdravila, kot je atorvastatin, za zniževanje holesterola), proti kislini odporne tablete ali kapsule, ki ne smejo predolgo ostati v želodcu, boste morda morali vzeti vsaj eno uro pred injiciranjem zdravila Suliqua ali štiri ure po injiciranju.
A. Check the name and expiry date on the label of your pen.
A. Preverite ime zdravila in datum izteka roka uporabnosti na nalepki peresnika.
• Angiotensin converting enzyme (ACE) inhibitors, for heart problems or high blood pressure.
• Zaviralce angiotenzinske konvertaze (ACE), za težave s srcem ali visok krvni tlak.
Suliqua should be injected once a day within one hour prior to a meal.
Zdravilo Suliqua je treba injicirati enkrat na dan, največ eno uro pred obrokom.
There is no therapeutic experience in patients with severe renal impairment (creatinine clearance less than 30 ml/min) or end-stage renal disease.
Pri bolnikih s hudo okvaro ledvic (očistek kreatinina manj kot 30 ml/min) ali končno odpovedjo ledvic ni terapevtskih izkušenj.
If you forget to use Suliqua
Če ste pozabili uporabiti zdravilo Suliqua
What you need to know before you use Suliqua Do not use Suliqua:
Kaj morate vedeti, preden boste uporabili zdravilo Suliqua Ne uporabljajte zdravila Suliqua
Suliqua should be used with caution in patients receiving oral medicinal products that require rapid gastrointestinal absorption, require careful clinical monitoring or have a narrow therapeutic ratio.
Zdravilo Suliqua je treba previdno uporabljati pri bolnikih, zdravljenih s peroralnimi zdravili, ki zahtevajo hitro absorpcijo v prebavilih, zahtevajo natančen klinični nadzor ali imajo ozko terapevtsko okno.
30-60 dose steps SoloStar
DRUGI PODATKI 30-60 odmernih korakov SoloStar
Increase in heart rate has been reported with GLP1RA use and a transient increase was also observed in some studies with lixisenatide.
Med uporabo agonistov receptorjev GLP-1 so poročali o povečanju srčne frekvence; prehodno povečanje so ugotovili tudi v nekaterih študijah z liksisenatidom.
The injection sites should be rotated within the same region (abdomen, deltoid, or thigh) from one injection to the next to reduce the risk of lipodystrophy (see section 4.8).
Mesta injiciranja je treba na posameznem predelu (trebuh, deltoidni predel ali stegno) od injekcije do injekcije krožno menjati, da bi zmanjšali tveganje za lipodistrofijo (glejte poglavje 4.8).
The apparent volume of distribution of lixisenatide after subcutaneous administration of insulin glargine/lixisenatide combinations (Vz/F) is approximately 100 L. The apparent volume of distribution of insulin glargine after subcutaneous administration of the insulin glargine/lixisenatide combinations (Vss/F) is approximately 1700 L.
Navidezni volumen porazdelitve liksisenatida po subkutani uporabi kombinacije insulina glargin in liksisenatida (Vz/F) je približno 100 l. Navidezni volumen porazdelitve insulina glargin po subkutani uporabi kombinacije insulina glargin in liksisenatida (Vss/F) je približno 1700 l.
The following related adverse reactions from clinical investigations are listed below by system organ class and in order of decreasing frequency (very common: ≥1/10; common: ≥1/100 to <1/10;
Naslednji povezani neželeni učinki, ugotovljeni v kliničnih raziskavah, so navedeni spodaj po organskih sistemih in razvrščeni po padajoči pogostnosti (zelo pogosti: ≥ 1/10, pogosti: ≥ 1/100 do < 1/10, občasni: ≥ 1/1.000 do < 1/100, redki: ≥ 1/10.000 do < 1/1.000, zelo redki: < 1/10.000).
Neither status for anti-insulin glargine antibodies nor for anti-lixisenatide antibodies had a clinically relevant impact on safety or efficacy.
Niti protitelesa proti insulinu glargin niti proti liksisenatidu niso klinično pomembno vplivala na varnost in učinkovitost.
STEP 5: Inject the dose
KORAK: Injicirajte odmerek
Suliqua is indicated in combination with metformin for the treatment of adults with type 2 diabetes mellitus to improve glycaemic control when this has not been provided by metformin alone or metformin combined with another oral glucose lowering medicinal product or with basal insulin (see section 4.4 and 5.1 for available data on the different combinations).
Zdravilo Suliqua je v kombinaciji z metforminom indicirano za zdravljenje odraslih s sladkorno boleznijo tipa 2 za izboljšanje urejenosti glikemije, če to ni bilo doseženo z metforminom samim ali v kombinaciji z drugim peroralnim zdravilom za zniževanje glukoze ali z bazalnim insulinom (glejte poglavji 4.4 in 5.1 za razpoložljive podatke o različnih kombinacijah).
Hypoglycaemia was the most frequently reported observed adverse reaction during treatment with Suliqua (see section 4.8).
Hipoglikemija je bila najpogosteje opažen neželeni učinek med zdravljenjem z zdravilom Suliqua (glejte poglavje 4.8).
Do not leave the pen in a car on an exceptionally warm or cold day.
Ob zelo vročih ali zelo hladnih dneh peresnika ne puščajte v avtu.
Results at 30 weeks -Study Type 2 Diabetes Uncontrolled on Basal Insulin mITT population Suliqua
Rezultati po 30 tednih - Študija sladkorne bolezni tipa 2, neurejene z bazalnim insulinom, populacija mZNZ Zdravilo Suliqua
• Protease inhibitors, for HIV.
• Zaviralce proteaz, za HIV.
• Take care when handling needles to prevent needle injury and cross-infection.
• Pri ravnanju z iglami bodite previdni, da boste preprečili poškodbe z iglo in navzkrižno okužbo.
Always use a new needle.
Vedno uporabite novo iglo.
Insulin and its analogs lower blood glucose by stimulating peripheral glucose uptake, especially by skeletal muscle and fat, and by inhibiting hepatic glucose production.
Insulin in njegovi analogi zmanjšajo koncentracijo glukoze v krvi, ker spodbujajo periferni privzem glukoze, zlasti v skeletnem mišičju in maščevju, in zavirajo nastajanje glukoze v jetrih.
Gastro-resistant formulations containing substances sensitive to stomach degradation, should be administered 1 hour before or 4 hours after lixisenatide injection.
Gastrorezistentne oblike zdravil, ki vsebujejo snovi, občutljive na razgradnjo v želodcu, je treba uporabiti 1 uro pred injiciranjem liksisenatida ali 4 ure po injiciranju.
How to store your pen Before first use
Shranjevanje peresnika Pred prvo uporabo
• Do not put the inner needle cap back on.
• Notranjega pokrovčka igle ne nameščajte nazaj.
Close glucose monitoring is recommended during the transfer and in the following weeks.
Med prehodom in v naslednjih tednih je priporočljiv natančen nadzor glukoze.
A postprandial injection of Lixisenatide also slows gastric emptying thereby reducing the rate at which meal-derived glucose is absorbed and appears in the circulation.
Postprandialno injiciranje liksisenatida upočasni tudi praznjenje želodca in tako zmanjša hitrost, s katero se glukoza iz obroka absorbira in se pojavi v krvnem obtoku.
• severe pain in your stomach area (abdomen) that will not go away.
• če imate hude bolečine v trebuhu, ki ne minejo.
Having too low or too high blood sugar (see information in the box at the end of this leaflet)can affect your ability to drive and use tools or machines.
Vpliv na sposobnost upravljanja vozil in strojev Prenizek ali previsok krvni sladkor (glejte informacije v okviru na koncu tega navodila za uporabo) lahko vplivata na sposobnost vožnje, uporabe orodij in upravljanja s stroji.
The randomised type 2 diabetes population had the following characteristics: Mean age was 58.4 years with the majority (57.1%) being aged of 50 to 64 years, and 50.6 percent were male.
Randomizirana populacija s sladkorno boleznijo tipa 2 je imela naslednje značilnosti: povprečna starost je bila 58,4 leta; večina (57,1 %) bolnikov je bila stara od 50 do 64 let.
Reasons why hypoglycaemia may happen:
Razlogi, zaradi katerih se lahko pojavi hipoglikemija:
In clinical studies with insulin glargine (100 units/ml) the glucose-lowering effect on a molar basis (i.e., when given at the same doses) of intravenous insulin glargine is approximately the same as that for human insulin.
V kliničnih študijah z insulinom glargin (100 enot/ml) je bil učinek intravensko uporabljenega insulina glargin na znižanje glukoze na molarni osnovi (tj. uporabljenega v enakih odmerkih) približno tolikšen kot učinek humanega insulina.
10-40 dose steps SoloStar
DRUGI PODATKI 10-40 odmernih korakov SoloStar
At all time points, 30-week mean plasma glucose values were lower in the Suliqua group than in both the insulin glargine group and the lixisenatide group, with the only exception of the pre-breakfast value which was similar between the Suliqua group and the insulin glargine group.
30-tedenske povprečne vrednosti glukoze v plazmi so bile na vseh časovnih točkah nižje v skupini z zdravilom Suliqua kot v skupinah z insulinom glargin in liksisenatidom; edina izjema je vrednost pred zajtrkom, ki je bila v skupini z zdravilom Suliqua podobna kot v skupini z insulinom glargin.
• Your healthcare professional will explain the design and features of your Suliqua pen, including how the dose counter of the pre-filled pen device shows the number of dose steps to be injected.
• Vaš zdravnik vam bo razložil zasnovo in lastnosti peresnika Suliqua, vključno s tem, kako števec odmerkov na tem napolnjenem injekcijskem peresniku prikazuje število odmernih korakov, ki bodo injicirani.
• Do not put your pen back in the refrigerator.
• Peresnika ne dajte nazaj v hladilnik.
Check that the medicine is clear.
Preverite, da je zdravilo bistro.
• throw the pen away and use a new one.
• zavrzite ta injekcijski peresnik in uporabite novega.
Suliqua is available in two pens, providing different dosing options, i.e. Suliqua (10-40) pen, Suliqua (30-60) pen respectively.
Zdravilo Suliqua je na voljo v dveh peresnikih, ki omogočata različno odmerjanje, tj. v peresniku Suliqua (10-40) in peresniku Suliqua (30-60).
• If the patient starts with the Suliqua (10-40) pen, the dose may be titrated up to 40 dose steps with this pen.
• Če bolnik začne zdravljenje s peresnikom Suliqua (10-40), je mogoče odmerek s tem peresnikom prilagoditi do odmerka 40 odmernih korakov.
Do not inject Suliqua.
Ne injicirajte si zdravila Suliqua.
Of the 1479 patients who started the run-in phase, 1170 were randomised.
Randomiziranih je bilo 1170 od 1479 bolnikov, ki so vstopili v obdobje uvajanja.
The impact of the combination of insulin glargine and lixisenatide on the pharmacodynamics of lixisenatide has not been studied in phase 1 studies.
Vpliva kombinacije insulina glargin in liksisenatida na farmakodinamiko liksisenatida v študijah 1. faze niso raziskali.
Handling needles • Take care when handling needles to prevent needle injury and cross-infection.
Ravnanje z iglami • Pri ravnanju z iglami bodite previdni, da boste preprečili poškodbe z iglo in navzkrižno okužbo.